Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tremelimumab”

215 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 215 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03164616
What this trial is testing

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Who this might be right for
Non Small Cell Lung Cancer NSCLC
AstraZeneca 1,186
Testing effectiveness (Phase 2)UnknownNCT03994393
What this trial is testing

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Who this might be right for
EGFR Mutant Advanced Non Small Cell Lung Cancer
University of Sydney 100
Early research (Phase 1)Study completedNCT02040064
What this trial is testing

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris 27
Large-scale testing (Phase 3)Looking for participantsNCT05557838
What this trial is testing

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Who this might be right for
Hepatocellular Carcinoma
AstraZeneca 210
Testing effectiveness (Phase 2)WithdrawnNCT05120622
What this trial is testing

Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder CancerHigh-Risk CancerTremelimumab+2 more
University of British Columbia
Testing effectiveness (Phase 2)Study completedNCT03317457
What this trial is testing

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Who this might be right for
Metastatic Adult Soft Tissue SarcomaRecurrent Adult Soft Tissue Sarcoma
AIO-Studien-gGmbH 103
Testing effectiveness (Phase 2)Active Not RecruitingNCT05000710
What this trial is testing

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Who this might be right for
Metastatic or Locally Advanced NSCLC
Sheba Medical Center 29
Testing effectiveness (Phase 2)Study completedNCT01853618
What this trial is testing

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Who this might be right for
Heptocellular CancerBiliary Tract NeoplasmsLiver Cancer+2 more
National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)Active Not RecruitingNCT05027425
What this trial is testing

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Who this might be right for
Hepatocellular CarcinomaCirrhosisPortal Hypertension
Davendra Sohal 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05883644
What this trial is testing

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Who this might be right for
Advanced Hepatocellular Carcinoma
AstraZeneca 111
Early research (Phase 1)Study completedNCT01975831
What this trial is testing

Evaluate MEDI4736 in Combination With Tremelimumab

Who this might be right for
Breast CancerOvarian CancerColorectal Cancer+2 more
Ludwig Institute for Cancer Research 104
Testing effectiveness (Phase 2)Looking for participantsNCT04430452
What this trial is testing

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8+4 more
Mary Feng, MD 21
Early research (Phase 1)Study completedNCT03085849
What this trial is testing

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Who this might be right for
Extensive-stage Small Cell Lung Cancer
Catherine Shu 2
Testing effectiveness (Phase 2)UnknownNCT04159974
What this trial is testing

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

Who this might be right for
Esophageal Adenocarcinoma
University of Cologne 56
Early research (Phase 1)Ended earlyNCT03277482
What this trial is testing

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Who this might be right for
Recurrent Gynecological CancerMetastatic Cervical CancerMetastatic Ovarian Cancer+8 more
Dana-Farber Cancer Institute 16
Large-scale testing (Phase 3)Active Not RecruitingNCT03703297
What this trial is testing

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Who this might be right for
Small Cell Lung Cancer
AstraZeneca 730
Testing effectiveness (Phase 2)Study completedNCT03871036
What this trial is testing

Improve Checkpoint-blockade Response in Advanced Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
The Netherlands Cancer Institute 53
Testing effectiveness (Phase 2)Study completedNCT03911557
What this trial is testing

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Who this might be right for
Tumor, Solid
John L. Villano, MD, PhD 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT05063565
What this trial is testing

TheraSphere With Durvalumab and Tremelimumab for HCC

Who this might be right for
Hepatocellular Carcinoma
Boston Scientific Corporation 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06008093
What this trial is testing

Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 100
Load More Results